ZURICH — Europe's drugs watchdog has recommended approving a meningitis vaccine made by Switzerland's Novartis, according to Reuters.
The European Medicines Agency said Dec. 18 that its Committee for Medicinal Products for Human Use backed use of Menveo for immunization of adolescents and adults at risk of exposure.
Novartis has said it expects the U.S Food and Drug Administration to rule on its Menveo meningitis vaccine in early 2010 after the regulator sought more information.
The panel also recommended a line extension for Novartis' top-selling high blood pressure drug Diovan as a tablet for children.
CHMP recommendations for marketing approval are normally endorsed by the European Commission within a couple of months.